Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. more
Time Frame | REVB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -18.27% | 0.49% | -1.93% |
1-Month Return | 17.77% | -3.1% | -3.69% |
3-Month Return | -33.91% | -8.59% | 0.82% |
6-Month Return | -70.29% | -4.57% | 3.51% |
1-Year Return | -96.25% | -0.94% | 21.91% |
3-Year Return | -99.99% | 2.88% | 24.73% |
5-Year Return | -99.99% | 35.84% | 78.4% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 95.81M | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | 69.17K | 40.01K | 25.05K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":57.84,"profit":true},{"date":"2023-12-31","value":36.22,"profit":true}] |
Gross Profit | 90.91M | - | (69.17K) | (40.01K) | (25.05K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.08,"profit":false},{"date":"2022-12-31","value":-0.04,"profit":false},{"date":"2023-12-31","value":-0.03,"profit":false}] |
Gross Margin | 94.88% | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 3.64K | 145.49K | 11.95M | 10.86M | 8.66M | [{"date":"2019-12-31","value":0.03,"profit":true},{"date":"2020-12-31","value":1.22,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.91,"profit":true},{"date":"2023-12-31","value":72.44,"profit":true}] |
Operating Income | (3.64K) | (145.49K) | (11.95M) | (10.86M) | (8.66M) | [{"date":"2019-12-31","value":-364000,"profit":false},{"date":"2020-12-31","value":-14549200,"profit":false},{"date":"2021-12-31","value":-1195048500,"profit":false},{"date":"2022-12-31","value":-1086451100,"profit":false},{"date":"2023-12-31","value":-865666400,"profit":false}] |
Total Non-Operating Income/Expense | 92.87M | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (3.64K) | (136.41K) | (11.99M) | (10.83M) | (120.25K) | [{"date":"2019-12-31","value":-363800,"profit":false},{"date":"2020-12-31","value":-13640800,"profit":false},{"date":"2021-12-31","value":-1198683700,"profit":false},{"date":"2022-12-31","value":-1082954900,"profit":false},{"date":"2023-12-31","value":-12025400,"profit":false}] |
Income Taxes | 11.60M | (3.80K) | (219.78K) | (34.96K) | 1.00 | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.03,"profit":false},{"date":"2021-12-31","value":-1.89,"profit":false},{"date":"2022-12-31","value":-0.3,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (11.60M) | - | - | - | - | [{"date":"2019-12-31","value":-1160363800,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | 31.70M | - | (11.99M) | (10.83M) | 875.06K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-37.82,"profit":false},{"date":"2022-12-31","value":-34.16,"profit":false},{"date":"2023-12-31","value":2.76,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (3.64K) | (136.41K) | (11.99M) | (10.79M) | (120.25K) | [{"date":"2019-12-31","value":-363800,"profit":false},{"date":"2020-12-31","value":-13640800,"profit":false},{"date":"2021-12-31","value":-1198683700,"profit":false},{"date":"2022-12-31","value":-1079458700,"profit":false},{"date":"2023-12-31","value":-12025400,"profit":false}] |
EPS (Diluted) | 2.61 | (187.20) | (155.01) | (24.44) | (6.21) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7172.25,"profit":false},{"date":"2021-12-31","value":-5938.97,"profit":false},{"date":"2022-12-31","value":-936.4,"profit":false},{"date":"2023-12-31","value":-237.93,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
REVB | |
---|---|
Cash Ratio | 1.61 |
Current Ratio | 1.64 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
REVB | |
---|---|
ROA (LTM) | -50.98% |
ROE (LTM) | -270.02% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
REVB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.60 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.40 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
REVB | |
---|---|
Trailing PE | NM |
Forward PE | 7.79 |
P/S (TTM) | 2.88 |
P/B | 1.81 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Revelation Biosciences Inc (REVB) share price today is $0.487
Yes, Indians can buy shares of Revelation Biosciences Inc (REVB) on Vested. To buy Revelation Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in REVB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Revelation Biosciences Inc (REVB) via the Vested app. You can start investing in Revelation Biosciences Inc (REVB) with a minimum investment of $1.
You can invest in shares of Revelation Biosciences Inc (REVB) via Vested in three simple steps:
The 52-week high price of Revelation Biosciences Inc (REVB) is $14.93. The 52-week low price of Revelation Biosciences Inc (REVB) is $0.28.
The price-to-earnings (P/E) ratio of Revelation Biosciences Inc (REVB) is
The price-to-book (P/B) ratio of Revelation Biosciences Inc (REVB) is 1.81
The dividend yield of Revelation Biosciences Inc (REVB) is 0.00%
The market capitalization of Revelation Biosciences Inc (REVB) is $3.93M
The stock symbol (or ticker) of Revelation Biosciences Inc is REVB